gutflix
GI learning, personalised

Summary

HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB

Geert R. D'Haens

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

In a prospective study of 40 ulcerative colitis patients treated with tofacitinib for 8 weeks, 58% achieved histological remission and responders showed significantly lower STAT1, JAK2, and STAT2 expression at week 8 compared to non-responders.

KEY POINTS

- 85% of patients achieved histological response and 58% achieved histological remission after 8 weeks of tofacitinib 10 mg twice daily, including 78% who had failed prior anti-TNF therapy and 55% who had failed vedolizumab
- Total STAT1, STAT3, and STAT5 expression significantly decreased after 8 weeks treatment in the entire cohort regardless of response status
- Responders to tofacitinib had significantly lower total STAT1 levels at week 8 compared to non-responders, and also showed significantly lower JAK2 and STAT2 expression at week 8
- Responders tended to express lower baseline JAK1, JAK2, and STAT4 levels and higher baseline STAT6 levels compared to non-responders, suggesting potential baseline predictors of response
- This prospective immunohistochemistry study may interest clinicians treating refractory ulcerative colitis and researchers investigating JAK-STAT pathway biomarkers for treatment response prediction

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/d6823ce2-743c-11ee-925c-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.